



ASX: LCT - OTCQX: LVCLY

Diabetes – Neurodegenerative Diseases – Cell Encapsulation

Investor Summary

June 2012

Andrea Grant
CEO

agrant@lctglobal.com; +64 210 785 421




SAFE HARBOR STATEMENT

This document contains certain forward-looking statements, relating to LCT's business, which can be identified by the use of forward-looking terminology such as "promising", "plans", "anticipated", "will", "project", "believe", "forecast", "expected", "estimated", "targeting", "aiming", "set to", "potential", "seeking to", "goal", "could provide", "intends", "is being developed", "could be", "on track", or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other health authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. LCT is providing this information as of the date of this presentation and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.




A CELL THERAPY COMPANY.....



NTCELL

NEW HOPE IN PARKINSON'S DISEASE

5m patients globally
Small molecule \$2bn



DIABECCELL[®]

BREAKTHROUGH IN TYPE 1 DIABETES

30m patients globally
Small molecule \$20bn



Andrea Grant agrant@lctglobal.com; +64 210 785 421

WITH A DIFFERENCE.....

Pathogen free, null virus
IP: US, EU, world



GMP facility
Internationally unique




Clinical grade encapsulation of cells
Removes need for immunosuppressants



Andrea Grant agrant@lctglobal.com; +64 210 785 421

PRODUCTS ADVANCING IN THE CLINIC....



A MAJOR PHARMACEUTICAL PARTNER

Shareholder certainty for lead candidate DIABECCELL

- A\$25m cash to take DIABECCELL to market by 2016
- NZ Ltd company, Exclusive to Diabetes field
- 50:50 Board
- Otsuka as a committed partner:
 - US\$20bn assets; US\$4bn cash
 - Capability across entire value chain from R&D through to Market
- LCT retains 50% ownership in JV fixed assets
 - Pig herd, facilities, DIABECCELL IP
- LCT retains 50% of downstream DIABECCELL profits
 - Unprecedented Biotech profit share




FREEDOM TO OPERATE OUTSIDE OF JV

LCT retains:

- Service fee income for development of DIABCECELL
 - cash flow
- Perpetual, exclusive license to exploit IP outside Diabetes field
- All staff (know-how)
- 100% ownership of encapsulation IP
- 100% of downstream profits from all non-DIABCECELL products
 - **NTCELL entering Phase I for Parkinson's early 2013**





NTCELL PRE-CLINICAL STUDIES PARKINSONS




NTCELL FOR PARKINSON'S


Un-precedented Pre-clinical data in primate models



Empty



NT



FUNDAMENTALS FOR SUCCESS ARE IN PLACE

Governance	✓	Cash flow	✓
Management	✓	Strategic partners	✓
Products	✓	Market	✓
Assets, including IP		✓	



.....Growth capital is important to meet milestones

Investment Opportunities:

Discounted Private placements (ASX 15% rule)

Rights issue

FOO

LCT FINANCIALS

Market Cap (16/5/2012)	
Current price	0.53
Shares outstanding (number)	339m
Market Cap (AUD)	18m
Capital to date (AUD)	64m
52 wk Hi/Low	0.12-0.04
Cash on hand	2.6m
Current burn	2.4m per annum

(ASX: LCT; OTCQX: LVCLY)



Andrea Grant agrant@lctglobal.com; +64 210 785 421